Description
Non-Fucosylated Anti-Human CD40 (SEA-CD40) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Cancer and carcinomas
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD40 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD40
Full Name
CD40 Molecule
Background
CD40 (CD40 Molecule) is a Protein Coding gene.
Diseases associated with CD40 include Immunodeficiency With Hyper-Igm, Type 3 and Cd40 Ligand Deficiency.
Among its related pathways are NLR Proteins and Cytokine Signaling in Immune system.
Gene Ontology (GO) annotations related to this gene include enzyme binding and receptor activity.
An important paralog of this gene is TNFRSF11A.
Alternative Names
Tumor necrosis factor receptor superfamily member 5; TNFRSF5; p50
Gene ID
958
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
SEA-CD40
Description
Non-Fucosylated Anti-Human CD40 (SEA-CD40) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Cancer and carcinomas
